Becton, Dickinson and Company $BDX Stock: Robeco Institutional Asset Management B.V. Boosts Holdings

Posted by Francis Steltz on Oct 24th, 2026

Robeco Institutional Asset Management B.V. grew its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 271.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,520 shares of the medical instruments supplier’s stock after acquiring an additional 116,612 shares during the period. Robeco Institutional Asset Management B.V. owned 0.06% of Becton, Dickinson and Company worth $28,554,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in Becton, Dickinson and Company during the second quarter valued at approximately $3,721,533,000. Bank of America Corp DE acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $474,993,000. First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $247,372,000. Finally, Deutsche Bank AG bought a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $204,226,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.7%

Becton, Dickinson and Company stock opened at $198.96 on Friday. The company’s 50-day moving average price is $185.41 and its two-hundred day moving average price is $165.10. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $54.82 billion, a P/E ratio of 59.93, a P/E/G ratio of 13.51 and a beta of 0.21. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,906 shares of company stock worth $1,265,855 in the last ninety days. 0.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Piper Sandler increased their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Zacks Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Barclays initiated coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price target for the company. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $185.07.

Get Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.